Literature DB >> 29891595

Effect of the Novel Antifungal Drug F901318 (Olorofim) on Growth and Viability of Aspergillus fumigatus.

Saskia du Pré1,2, Nicola Beckmann3, Mariana Cruz Almeida4, Graham E M Sibley3, Derek Law3, Alexandra C Brand4, Mike Birch3, Nick D Read2, Jason D Oliver3.   

Abstract

F901318 (olorofim) is a novel antifungal drug that is highly active against Aspergillus species. Belonging to a new class of antifungals called the orotomides, F901318 targets dihydroorotate dehydrogenase (DHODH) in the de novo pyrimidine biosynthesis pathway. In this study, the antifungal effects of F901318 against Aspergillus fumigatus were investigated. Live cell imaging revealed that, at a concentration of 0.1 μg/ml, F901318 completely inhibited germination, but conidia continued to expand by isotropic growth for >120 h. When this low F901318 concentration was applied to germlings or vegetative hyphae, their elongation was completely inhibited within 10 h. Staining with the fluorescent viability dye bis-(1,3-dibutylbarbituric acid) trimethine oxonol (DiBAC) showed that prolonged exposure to F901318 (>24 h) led to vegetative hyphal swelling and a decrease in hyphal viability through cell lysis. The time-dependent killing of F901318 was further confirmed by measuring the fungal biomass and growth rate in liquid culture. The ability of hyphal growth to recover in drug-free medium after 24 h of exposure to F901318 was strongly impaired compared to that of the untreated control. A longer treatment of 48 h further improved the antifungal effect of F901318. Together, the results of this study indicate that F901318 initially has a fungistatic effect on Aspergillus isolates by inhibiting germination and growth, but prolonged exposure is fungicidal through hyphal swelling followed by cell lysis.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Aspergillus fumigatus; F901318; antifungal agents; aspergillosis; filamentous fungi; olorofim; orotomide

Mesh:

Substances:

Year:  2018        PMID: 29891595      PMCID: PMC6105813          DOI: 10.1128/AAC.00231-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

1.  Conidial germination in Aspergillus nidulans requires RAS signaling and protein synthesis.

Authors:  N Osherov; G May
Journal:  Genetics       Date:  2000-06       Impact factor: 4.562

2.  Germinated and nongerminated conidial suspensions for testing of susceptibilities of Aspergillus spp. to amphotericin B, itraconazole, posaconazole, ravuconazole, and voriconazole.

Authors:  A Espinel-Ingroff
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

3.  Method for measuring postantifungal effect in Aspergillus species.

Authors:  Roxana G Vitale; Johan W Mouton; Javier Afeltra; Jacques F G M Meis; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

4.  In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates.

Authors:  J B Buil; A J M M Rijs; J F Meis; M Birch; D Law; W J G Melchers; P E Verweij
Journal:  J Antimicrob Chemother       Date:  2017-09-01       Impact factor: 5.790

5.  Organism-dependent fungicidal activities of azoles.

Authors:  E K Manavathu; J L Cutright; P H Chandrasekar
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

6.  Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors.

Authors:  L D Fairbanks; M Bofill; K Ruckemann; H A Simmonds
Journal:  J Biol Chem       Date:  1995-12-15       Impact factor: 5.157

7.  The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro.

Authors:  J C Bowman; P Scott Hicks; M B Kurtz; H Rosen; D M Schmatz; P A Liberator; C M Douglas
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

8.  Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors.

Authors:  Mihai G Netea; Neil A R Gow; Carol A Munro; Steven Bates; Claire Collins; Gerben Ferwerda; Richard P Hobson; Gwyneth Bertram; H Bleddyn Hughes; Trees Jansen; Liesbeth Jacobs; Ed T Buurman; Karlijn Gijzen; David L Williams; Ruurd Torensma; Alistair McKinnon; Donna M MacCallum; Frank C Odds; Jos W M Van der Meer; Alistair J P Brown; Bart Jan Kullberg
Journal:  J Clin Invest       Date:  2006-05-18       Impact factor: 14.808

9.  Host carbon sources modulate cell wall architecture, drug resistance and virulence in a fungal pathogen.

Authors:  Iuliana V Ene; Ashok K Adya; Silvia Wehmeier; Alexandra C Brand; Donna M MacCallum; Neil A R Gow; Alistair J P Brown
Journal:  Cell Microbiol       Date:  2012-06-05       Impact factor: 3.715

10.  Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus flavus.

Authors:  Clara E Negri; Adam Johnson; Laura McEntee; Helen Box; Sarah Whalley; Julie A Schwartz; V Ramos-Martín; Joanne Livermore; Ruwanthi Kolamunnage-Dona; Arnaldo L Colombo; William W Hope
Journal:  J Infect Dis       Date:  2018-03-13       Impact factor: 5.226

View more
  21 in total

Review 1.  Aspergillus fumigatus and aspergillosis: From basics to clinics.

Authors:  A Arastehfar; A Carvalho; J Houbraken; L Lombardi; R Garcia-Rubio; J D Jenks; O Rivero-Menendez; R Aljohani; I D Jacobsen; J Berman; N Osherov; M T Hedayati; M Ilkit; D James-Armstrong; T Gabaldón; J Meletiadis; M Kostrzewa; W Pan; C Lass-Flörl; D S Perlin; M Hoenigl
Journal:  Stud Mycol       Date:  2021-05-10       Impact factor: 16.097

Review 2.  The Future of Antifungal Drug Therapy: Novel Compounds and Targets.

Authors:  Caroline Mota Fernandes; Deveney Dasilva; Krupanandan Haranahalli; J Brian McCarthy; John Mallamo; Iwao Ojima; Maurizio Del Poeta
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

Review 3.  Progress and challenges in fungal lung disease in cystic fibrosis.

Authors:  Gina Hong
Journal:  Curr Opin Pulm Med       Date:  2022-09-19       Impact factor: 2.868

Review 4.  Novel Promising Antifungal Target Proteins for Conquering Invasive Fungal Infections.

Authors:  Cheng Zhen; Hui Lu; Yuanying Jiang
Journal:  Front Microbiol       Date:  2022-06-16       Impact factor: 6.064

5.  Olorofim Effectively Eradicates Dermatophytes In Vitro and In Vivo.

Authors:  Esmat Mirbzadeh Ardakani; Atefeh Sharifirad; Nasrin Pashootan; Mahsa Nayebhashemi; Mozhgan Zahmatkesh; Somayeh Enayati; Mehdi Razzaghi-Abyaneh; Vahid Khalaj
Journal:  Antimicrob Agents Chemother       Date:  2021-09-27       Impact factor: 5.191

6.  Genetic validation of Aspergillus fumigatus phosphoglucomutase as a viable therapeutic target in invasive aspergillosis.

Authors:  Kaizhou Yan; Mathew Stanley; Bartosz Kowalski; Olawale G Raimi; Andrew T Ferenbach; Pingzhen Wei; Wenxia Fang; Daan M F van Aalten
Journal:  J Biol Chem       Date:  2022-04-30       Impact factor: 5.486

7.  In Vitro Activity of Novel Antifungal Olorofim against Filamentous Fungi and Comparison to Eight Other Antifungal Agents.

Authors:  Ourania Georgacopoulos; Natalie S Nunnally; Eric M Ransom; Derek Law; Mike Birch; Shawn R Lockhart; Elizabeth L Berkow
Journal:  J Fungi (Basel)       Date:  2021-05-12

8.  The Dynamic Influence of Olorofim (F901318) on the Cell Morphology and Organization of Living Cells of Aspergillus fumigatus.

Authors:  Saskia du Pré; Mike Birch; Derek Law; Nicola Beckmann; Graham E M Sibley; Michael J Bromley; Nick D Read; Jason D Oliver
Journal:  J Fungi (Basel)       Date:  2020-04-10

9.  Prevalence and Therapeutic Challenges of Fungal Drug Resistance: Role for Plants in Drug Discovery.

Authors:  Lewis Marquez; Cassandra L Quave
Journal:  Antibiotics (Basel)       Date:  2020-03-31

10.  Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim.

Authors:  Wilson Lim; Kimberly Eadie; Mickey Konings; Bart Rijnders; Ahmed H Fahal; Jason D Oliver; Mike Birch; Annelies Verbon; Wendy van de Sande
Journal:  J Antimicrob Chemother       Date:  2020-04-01       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.